vs
Side-by-side financial comparison of FIRST COMMONWEALTH FINANCIAL CORP (FCF) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $133.7M, roughly 1.4× FIRST COMMONWEALTH FINANCIAL CORP). FIRST COMMONWEALTH FINANCIAL CORP runs the higher net margin — 28.1% vs 0.9%, a 27.2% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 13.0%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 5.5%).
First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
FCF vs FOLD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $133.7M | $185.2M |
| Net Profit | $37.5M | $1.7M |
| Gross Margin | — | 85.7% |
| Operating Margin | — | 8.6% |
| Net Margin | 28.1% | 0.9% |
| Revenue YoY | 13.0% | 23.7% |
| Net Profit YoY | 14.8% | -88.5% |
| EPS (diluted) | $0.37 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $133.7M | — | ||
| Q4 25 | $137.9M | $185.2M | ||
| Q3 25 | $136.0M | $169.1M | ||
| Q2 25 | $131.0M | $154.7M | ||
| Q1 25 | $118.0M | $125.2M | ||
| Q4 24 | $120.4M | $149.7M | ||
| Q3 24 | $121.2M | $141.5M | ||
| Q2 24 | $120.2M | $126.7M |
| Q1 26 | $37.5M | — | ||
| Q4 25 | $44.9M | $1.7M | ||
| Q3 25 | $41.3M | $17.3M | ||
| Q2 25 | $33.4M | $-24.4M | ||
| Q1 25 | $32.7M | $-21.7M | ||
| Q4 24 | $35.8M | $14.7M | ||
| Q3 24 | $32.1M | $-6.7M | ||
| Q2 24 | $37.1M | $-15.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | — | 90.6% | ||
| Q2 24 | — | 91.1% |
| Q1 26 | — | — | ||
| Q4 25 | 40.9% | 8.6% | ||
| Q3 25 | 38.1% | 20.3% | ||
| Q2 25 | 32.1% | -6.1% | ||
| Q1 25 | 34.8% | -6.3% | ||
| Q4 24 | 37.1% | 10.7% | ||
| Q3 24 | 33.4% | 15.3% | ||
| Q2 24 | 38.7% | 11.8% |
| Q1 26 | 28.1% | — | ||
| Q4 25 | 32.5% | 0.9% | ||
| Q3 25 | 30.4% | 10.2% | ||
| Q2 25 | 25.5% | -15.8% | ||
| Q1 25 | 27.7% | -17.3% | ||
| Q4 24 | 29.8% | 9.8% | ||
| Q3 24 | 26.5% | -4.8% | ||
| Q2 24 | 30.9% | -12.4% |
| Q1 26 | $0.37 | — | ||
| Q4 25 | $0.44 | $0.00 | ||
| Q3 25 | $0.39 | $0.06 | ||
| Q2 25 | $0.32 | $-0.08 | ||
| Q1 25 | $0.32 | $-0.07 | ||
| Q4 24 | $0.35 | $0.05 | ||
| Q3 24 | $0.31 | $-0.02 | ||
| Q2 24 | $0.36 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $293.5M |
| Total DebtLower is stronger | $154.9M | $392.7M |
| Stockholders' EquityBook value | $1.6B | $274.2M |
| Total Assets | $12.3B | $949.9M |
| Debt / EquityLower = less leverage | 0.10× | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $293.5M | ||
| Q3 25 | — | $263.8M | ||
| Q2 25 | — | $231.0M | ||
| Q1 25 | — | $250.6M | ||
| Q4 24 | — | $249.9M | ||
| Q3 24 | — | $249.8M | ||
| Q2 24 | — | $260.1M |
| Q1 26 | $154.9M | — | ||
| Q4 25 | $261.7M | $392.7M | ||
| Q3 25 | $262.1M | $392.0M | ||
| Q2 25 | $262.4M | $391.3M | ||
| Q1 25 | $262.7M | $390.7M | ||
| Q4 24 | $263.0M | $390.1M | ||
| Q3 24 | $136.3M | $389.5M | ||
| Q2 24 | $136.6M | $388.9M |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $274.2M | ||
| Q3 25 | $1.5B | $230.4M | ||
| Q2 25 | $1.5B | $204.3M | ||
| Q1 25 | $1.4B | $193.6M | ||
| Q4 24 | $1.4B | $194.0M | ||
| Q3 24 | $1.4B | $178.8M | ||
| Q2 24 | $1.4B | $132.5M |
| Q1 26 | $12.3B | — | ||
| Q4 25 | $12.3B | $949.9M | ||
| Q3 25 | $12.3B | $868.8M | ||
| Q2 25 | $12.2B | $815.3M | ||
| Q1 25 | $11.8B | $789.8M | ||
| Q4 24 | $11.6B | $785.0M | ||
| Q3 24 | $12.0B | $786.6M | ||
| Q2 24 | $11.6B | $749.5M |
| Q1 26 | 0.10× | — | ||
| Q4 25 | 0.17× | 1.43× | ||
| Q3 25 | 0.17× | 1.70× | ||
| Q2 25 | 0.17× | 1.92× | ||
| Q1 25 | 0.18× | 2.02× | ||
| Q4 24 | 0.19× | 2.01× | ||
| Q3 24 | 0.10× | 2.18× | ||
| Q2 24 | 0.10× | 2.93× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $16.3M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 8.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $187.5M | $16.3M | ||
| Q3 25 | $49.5M | $35.7M | ||
| Q2 25 | $30.4M | $-26.5M | ||
| Q1 25 | $55.9M | $7.8M | ||
| Q4 24 | $129.5M | $-3.9M | ||
| Q3 24 | $53.6M | $-23.0M | ||
| Q2 24 | $22.7M | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | $171.5M | $16.0M | ||
| Q3 25 | — | $35.3M | ||
| Q2 25 | — | $-28.9M | ||
| Q1 25 | — | $7.5M | ||
| Q4 24 | $113.9M | $-4.2M | ||
| Q3 24 | — | $-23.3M | ||
| Q2 24 | — | $21.6M |
| Q1 26 | — | — | ||
| Q4 25 | 124.3% | 8.6% | ||
| Q3 25 | — | 20.9% | ||
| Q2 25 | — | -18.7% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | 94.6% | -2.8% | ||
| Q3 24 | — | -16.5% | ||
| Q2 24 | — | 17.0% |
| Q1 26 | — | — | ||
| Q4 25 | 11.7% | 0.2% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | 12.9% | 0.2% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 4.18× | 9.62× | ||
| Q3 25 | 1.20× | 2.06× | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 1.71× | — | ||
| Q4 24 | 3.61× | -0.27× | ||
| Q3 24 | 1.67× | — | ||
| Q2 24 | 0.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FCF
Segment breakdown not available.
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
